Glucose-Lowering Agents in the Management of Nonalcoholic Fatty Liver Disease / 임상당뇨병
Journal of Korean Diabetes
; : 88-96, 2018.
Article
in Korean
| WPRIM (Western Pacific)
| ID: wpr-726884
Responsible library:
WPRO
ABSTRACT
Nonalcoholic fatty liver disease (NAFLD) is more prevalent in diabetic patients than in non-diabetic subjects, because the two diseases share a common pathophysiological mechanism. Associated abnormalities can be observed from the pre-diabetic stage. Lifestyle intervention, including diet, exercise, and weight loss, is the primary recommended therapy for NAFLD. Among the therapeutic drugs for NAFLD treatment, anti-diabetic agents are aimed at improving or slowing the progression of NAFLD in addition to lowering blood glucose. In this paper, we systemically review the evidence surrounding antidiabetic medications and their ability to improve disease progression in patients with NAFLD.
Full text:
Available
Database:
WPRIM (Western Pacific)
Main subject:
Blood Glucose
/
Weight Loss
/
Disease Progression
/
Thiazolidinediones
/
Diabetes Mellitus
/
Diet
/
Sodium-Glucose Transporter 2
/
Incretins
/
Non-alcoholic Fatty Liver Disease
/
Life Style
Limits:
Humans
Language:
Korean
Journal:
Journal of Korean Diabetes
Year:
2018
Document type:
Article